Loading...
25 metformin COVID-19 controlled studies,
1 RCTs
https://c19early.com/mfmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Reis (DB RCT) 6%
0.94 [0.55-1.61]
hosp.
24/215
24/203
Improvement, RR [CI] Treatment Control Reis (DB RCT) 39%
0.61 [0.26-1.41]
hosp.
8/168
14/179
Reis (DB RCT) -14%
1.14 [0.73-1.81]
hosp./ER
34/215
28/203
Reis (DB RCT) 12%
0.88 [0.45-1.71]
hosp./ER
14/168
17/179
Reis (DB RCT) 31%
0.69 [0.28-1.68]
progression
8/216
11/205
Reis (DB RCT) 26%
0.74 [0.29-1.90]
progression
7/171
10/181
Reis (DB RCT) 1%
0.99 [0.88-1.11]
viral+
215 (n)
203 (n)
Luo 75%
0.25 [0.07-0.84]
death
3/104
22/179
Wang 58%
0.42 [0.01-1.98]
death
1/9
13/49
Chen 33%
0.67 [0.20-1.78]
death
4/43
15/77
Li 78%
0.22 [0.09-0.54]
death
2/37
21/94
Li -27%
1.27 [0.12-13.6]
ventilation
1/37
2/94
Pérez-Belmo.. (PSM) -10%
1.10 [0.84-1.40]
death
79/249
79/249
Bramante 7%
0.93 [0.81-1.06]
death
394/2,333
791/3,923
Bramante 24%
0.76 [0.60-0.96]
death
1,129 (n)
2,173 (n)
Bramante -3%
1.03 [0.84-1.27]
death
1,204 (n)
1,750 (n)
Lalau (PSM) 22%
0.78 [0.55-1.10]
death
671 (n)
419 (n)
Lalau (PSM) 18%
0.82 [0.61-1.11]
int./death
671 (n)
419 (n)
Lalau (PSM) 7%
0.93 [0.64-1.35]
ventilation
671 (n)
419 (n)
Huh -1%
1.01 [0.75-1.37]
progression
104/272
774/2,533
Huh 4%
0.96 [0.82-1.12]
cases
population-based cohort
Crouse 61%
0.39 [0.16-0.87]
death
8/76
34/144
Lally 52%
0.48 [0.28-0.84]
death
16/127
144/648
Oh -26%
1.26 [0.81-1.95]
death
5,946 (n)
5,946 (n)
Oh (PSM) 28%
0.72 [0.63-0.81]
cases
390/5,946
541/5,946
Holt -27%
1.27 [0.72-2.22]
cases
12/429
434/14,798
Khunti 23%
0.77 [0.73-0.81]
death
population-based cohort
Jiang (PSM) 46%
0.54 [0.13-2.26]
death
3/74
10/74
Jiang (PSM) 80%
0.20 [0.05-0.77]
progression
8/74
17/74
Ghany 66%
0.34 [0.19-0.59]
death
392 (n)
747 (n)
Ghany 29%
0.71 [0.52-0.86]
hosp.
392 (n)
747 (n)
Ghany 68%
0.32 [0.22-0.45]
ARDS
392 (n)
747 (n)
Alamgir 27%
0.73 [0.63-0.84]
death
11,062 (n)
11,062 (n)
Alamgir 34%
0.66 [0.49-0.90]
death
5,369 (n)
5,369 (n)
Alamgir 30%
0.70 [0.53-0.95]
death
2,525 (n)
2,525 (n)
Ravindra 30%
0.70 [0.28-1.56]
death
5/53
57/313
Boye 10%
0.90 [0.86-0.94]
hosp.
2,067/4,250
3,196/5,281
Cheng (PSM) -65%
1.65 [0.71-3.86]
death
678 (n)
535 (n)
Wang 12%
0.88 [0.81-0.97]
ICU
6,504 (n)
10,000 (n)
Wander 15%
0.85 [0.80-0.90]
death
Wander 2%
0.98 [0.92-1.06]
ICU
Wander 3%
0.97 [0.94-1.01]
hosp.
Saygili (PSM) 42%
0.58 [0.37-0.92]
death
120 (n)
120 (n)
Ong 47%
0.53 [0.31-0.87]
death
33/186
57/169
Ong 24%
0.76 [0.50-1.10]
death
28/109
57/169
Ong 85%
0.15 [0.04-0.55]
death
2/40
57/169
Ong 76%
0.24 [0.07-0.68]
death
3/37
57/169
Ojeda-Ferná.. (PSM) 16%
0.84 [0.79-0.89]
death
1,476/6,556
1,787/6,556
Ojeda-Ferná.. (PSM) 22%
0.78 [0.72-0.84]
death
968/6,556
1,261/6,556
Ojeda-Ferná.. (PSM) 22%
0.78 [0.64-0.95]
ICU
166/6,556
212/6,556
Ojeda-Ferná.. (PSM) 3%
0.97 [0.94-1.00]
hosp.
3,551/6,556
3,670/6,556
Ojeda-Ferná.. (PSM) 8%
0.92 [0.84-1.00]
death
793/3,297
876/3,297
Ojeda-Ferná.. (PSM) 16%
0.84 [0.75-0.94]
death
512/3,297
618/3,297
Ojeda-Ferná.. (PSM) 39%
0.61 [0.44-0.82]
ICU
64/3,297
102/3,297
Ojeda-Ferná.. (PSM) -2%
1.02 [0.97-1.07]
hosp.
1,822/3,297
1,792/3,297
metformin COVID-19 outcomes c19early.com/mf Jan 16, 2022
Favors metformin
Favors control
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
WCH
and
FLCCC provide
treatment protocols.
Submit
